USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Subscribe To Our Newsletter & Stay Updated